🔗 Share this article

A shadow market for unapproved weight-loss drugs is being driven by TikTok fitness influencers and sellers on communication apps, according to new investigations.

Experimental Drug Acquiring Traction Online

The experimental drug, which remains in clinical trials, is being promoted by social media influencers for its supposed fat-burning properties. Followers are encouraged to message these accounts directly for source information, while also receiving promotional offers.

Thriving Trade on Messaging Platforms

Separately, a flourishing trade exists on messaging services, where communities with numerous of participants share comparison images, injection guides and claims of rapid UK delivery. Sellers promote the substance there before redirecting buyers to other platforms for purchases.

Understanding The Experimental Drug

This medication is an investigational injection developed by US drugmaker Eli Lilly. The drug targets three intestinal hormones – glucagon-like peptide-1, glucose-dependent insulinotropic polypeptide and pancreatic hormone. Preliminary studies suggest it could assist patients lose up to 25% of their body weight. Referred to as the “triple G”, the drug is being promoted online as the successor to Ozempic.

Medical Professionals Voice Concerns

However, physicians and chemists have cautions that the sale of what is still an unapproved medication in the United Kingdom is worrisome and could result in users injecting substances of unknown origin.

Several professionals stated the demand for retatrutide could be linked to the increasing price of approved slimming treatments such as Mounjaro.

Legal Status and Implementation

Selling the unapproved drug on social media or messaging apps is prohibited in the UK, as it is an unapproved drug that cannot be marketed or distributed for human use under the Human Medicines Regulations 2012.

Some influencers attempt to circumvent the rules by referring to the substance as a “research chemical” or describing it as “not for human consumption”. The substance is not a controlled substance, but advertising and distribution can still violate medicines, advertising, and consumer regulations, potentially leading to penalties, prosecution or prison.

Service Response and Content Removal

According to the social media company, the platform has taken down violative material and banned related hashtags and search suggestions. The company said it was dedicated to keeping the platform safe and investing in enhancing enforcement strategies.

Digital Marketplace Operations

Research also discovered groups with up to 9,000 participants selling retatrutide using Telegram's built-in discovery tool, which functions like a public directory. Entering “retatrutide” immediately displays groups with numerous of users, populated with images of weight loss, glowing testimonials and step-by-step guides for mixing or administering at residence.

After minutes of entering one community, a vendor shared contact information, where most purchases occur. The vendor provided an guidebook and promised shipping within 48 hours. When asked whether the substance was genuine, one vendor said: “You can’t be sure.” Another shared a photo of a supposed laboratory certificate. None asked about body mass, medical conditions or previous experience.

Product Information and Pricing

Within these communities, posts display dark colored packages with postal service labels, stating to include new batches. One communication stated: “It took eight of us to load them this morning.”

Customers can select between powder vials, mixed at home with purified liquid, or ready-to-use injectors typically sold at £160 for 20 milligrams. When questioned how long a pen should last, sellers give conflicting responses varying between a few weeks to “depends on your body”.

Platform Oversight and Safety Actions

A representative for Telegram stated it actively monitored harmful content on its platform including content that encouraged the “misuse of controlled medications”. The organization added that it removed “millions of pieces of harmful content each day”.

Healthcare Expert Cautions

“People are injecting substances they can’t verify. Although the research behind retatrutide is sound, these online versions may not contain what they claim,” said Jason Murphy, the head of pharmaceutical services at Chemist4U.

Dr Crystal Wyllie of Asda Online Doctor linked the surge in interest to current price rises for approved weight-loss medications such as Mounjaro. “With prices rising, individuals are turning to online platforms. But counterfeit injections are highly risky. You can’t be certain what’s contained or whether the conditions they were made in was sterile,” she said.

Her staff has previously encountered patients injured by personal administration from unverified sources. “We understand the disappointment, but purchasing from messaging apps or WhatsApp is gambling with your health,” said Wyllie. “These substances could be impure or incorrectly dosed.”

Producer Statement

A representative from the pharmaceutical company said the substance was in phase 3 clinical trials and had not been evaluated or authorized by any regulatory agency globally. “Consequently at this time no one can sell [it] for personal consumption,” they said, noting that any product “misleadingly claiming itself as a Lilly investigational substance not yet authorized … may subject users to possibly serious health risks”.